Frederick E. Durr - Concepedia

Author

Frederick E. Durr

American Medical Research

Also Known As

F Dürr, F E DURR, F E Durr, F. Dürr, F. E. DURR, F. E. Durr, F.E. Durr, FREDERICK E. DURR, Frederick E. Durr, L Wolf

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

American Medical Research Pfizer (United States)Pearl River Community College Pearl River Hydraulic Research Institute

About

Frederick E. Durr is an author at American Medical Research specializing in medicine, pharmacology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	18	1.1K
2	Biochemistry	4	4	139
3	Natural Sciences	3	3	67
4	Allergy	2	2	32
5	Health Sciences	1	1	238

Frederick E. Durr

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones K. C. Murdock, Ralph G. Child, P. F. FABIO, Journal of Medicinal Chemistry Medicinal ChemistryAntitumor AgentsMedicineAnti-cancer AgentColon Tumor 26	1979	283
Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Lois M. Hinman, Philip R. Hamann, Ryan M. Wallace, PubMed Rhamnose ResidueCalicheamicin FamilyPharmacotherapyAntimicrobial ChemotherapyPharmaceutical Chemistry	1993	238
Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice. Roslyn E. Wallace, K. C. Murdock, Robert B. Angier, PubMed Chemoprevention StrategyImmunologyMetronomic ChemotherapyPharmaceutical ChemistryTumor Biology	1979	149
Studies on the infectivity and cytopathology of epstein‐barr virus in human lymphoblastoid cells Frederick E. Durr, James H. Monroe, Rene W. Schmitter, International Journal of Cancer Epstein‐barr VirusViral ReplicationHuman Lymphoblastoid CellsImmunologyViral Pathogenesis	1970	82
An Anti-MUC1 Antibody−Calicheamicin Conjugate for Treatment of Solid Tumors. Choice of Linker and Overcoming Drug Resistance Philip R. Hamann, Lois M. Hinman, Carl F. Beyer, Bioconjugate Chemistry	2005	74
Development of mitoxantrone Richard White, Frederick E. Durr Investigational New Drugs BiochemistryMedicineToxicologyExperimental ToxicologyPharmacology	1985	72
Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice. Ronald V. Citarella, Roslyn E. Wallace, K. C. Murdock, PubMed Chemoprevention StrategyCl 216942Pharmaceutical ChemistryTumor BiologyExperimental Tumors	1982	34
Characterization of the DNA of herpesviruses associated with Lucké adenocarcinoma of the frog and Burkitt lymphoma of man Edward K. Wagner, Bernard Roizman, Thérèse Savage, Virology Lucké AdenocarcinomaPathogenesisPathologyVirologyHerpesviruses	1970	32
Efficacy of 1-β- <scp>d</scp> -Ribofuranosyl-1,2,4-Triazole-3-carboxamide Against Influenza Virus Infections in Mice Frederick E. Durr, H. F. Lindh, Martin Forbes Antimicrobial Agents and Chemotherapy	1975	31
P-glycoprotein mediates profound resistance to bisantrene. X. P. Zhang, M K Ritke, Jack C. Yalowich, PubMed PharmacotherapyLow LevelsAnthracene DerivativesDrug ResistanceMolecular Pharmacology	1994	29

Page 1